You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Charles Bonnet syndrome improves when treatment is effective in age-related macular degeneration
  1. A Singh,
  2. T L Sørensen
  1. Department of Ophthalmology, Copenhagen University Hospital, Roskilde, Roskilde, Denmark
  1. Correspondence to Dr Amardeep Singh, Department of Ophthalmology, Copenhagen University Hospital, Roskilde, DK-4000 Roskilde, Denmark; asingh{at}dadlnet.dk

https://doi.org/10.1136/bjo.2010.179465

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The Charles Bonnet syndrome (CBS) is characterised by vivid, complex and recurrent visual hallucinations occurring in psychologically normal people, and it is often associated with vision impairment.1 No effective treatment of CBS has been identified. We investigated whether intravitreal ranibizumab therapy for neovascular age-related macular degeneration (AMD) affects symptoms of CBS.

    Over a 3-month period, we asked all patients with neovascular AMD midway in treatment course with ranibizumab (n=220) about CBS symptoms using the following question: ‘Some patients with the same disease as you have report seeing things which they know are unreal. Have you experienced this?’2 A positive answer led to further questioning about the nature of the hallucinations. Patients with obvious signs or medical records of dementia were excluded, as were patients reporting …

    View Full Text

    Footnotes

    • Competing interests None.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.